Nuvectis Pharma Hosts Virtual Meeting on NXP900 Phase 1b Program in Advanced Solid Tumors
I'm PortAI, I can summarize articles.
Nuvectis Pharma Inc. will host a virtual meeting on December 2, 2025, to discuss the NXP900 Phase 1b Program in advanced solid tumors, including its combination with osimertinib for non-small cell lung cancer. The event will feature experts and cover key data and strategies, followed by a live Q&A session. A replay will be available on the company's website.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments